B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 139 Published: April 29, 2022 Report Code: GMDGDHC22138IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2022, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 7, 12, 1 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 1 molecules, respectively.

B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).

– The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • AB Science SA

    Alexion Pharmaceuticals Inc

    BeiGene Ltd

    Beijing Immunochina Pharmaceuticals Co Ltd

    BioIntegrator

    BioInvent International AB

    Biosplice Therapeutics Inc

    BioXpress Therapeutics SA

    Bristol-Myers Squibb Co

    Chengdu USino Technology Biology Co Ltd

    CRISPR Therapeutics AG

    Eisai Co Ltd

    Hangzhou Hezheng Pharmaceutical Co Ltd

    iDD biotech SAS

    Kuur Therapeutics Ltd

    Loxo Oncology Inc

    Mediolanum farmaceutici SpA

    Merck & Co Inc

    Nkarta Inc

    Nordic Nanovector ASA

    Regeneron Pharmaceuticals Inc

    Shanghai Pharmaceutical Group Co Ltd

    Tianweiyuan and Biomedicine Shanghai Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

B-Cell Chronic Lymphocytic Leukemia – Overview

B-Cell Chronic Lymphocytic Leukemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

B-Cell Chronic Lymphocytic Leukemia – Companies Involved in Therapeutics Development

B-Cell Chronic Lymphocytic Leukemia – Drug Profiles

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects

B-Cell Chronic Lymphocytic Leukemia – Discontinued Products

B-Cell Chronic Lymphocytic Leukemia – Product Development Milestones

Featured News & Press Releases

Feb 03, 2020: Calibr’s ‘switchable’ CAR-T platform for cancer moves forward with FDA clearance of Investigational New Drug application

Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by AB Science SA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Alexion Pharmaceuticals Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BeiGene Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioIntegrator, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioInvent International AB, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Biosplice Therapeutics Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioXpress Therapeutics SA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Bristol-Myers Squibb Co, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Chengdu USino Technology Biology Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by CRISPR Therapeutics AG, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Eisai Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Hangzhou Hezheng Pharmaceutical Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by iDD biotech SAS, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Kuur Therapeutics Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Loxo Oncology Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Mediolanum farmaceutici SpA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Merck & Co Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Nkarta Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Nordic Nanovector ASA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Regeneron Pharmaceuticals Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Tianweiyuan and Biomedicine Shanghai Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, 2022

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, 2022 (Contd..1)

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, 2022 (Contd..2)

B-Cell Chronic Lymphocytic Leukemia – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.